Pregled bibliografske jedinice broj: 620332
Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease
Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease // Progress in neuro-psychopharmacology & biological psychiatry, 44 (2013), 94-99 doi:10.1016/j.pnpbp.2013.02.002 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 620332 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease
Autori
Mustapić, Maja ; Presečki, Paola ; Pivac, Nela ; Mimica, Ninoslav ; Hof, Patrick R. ; Šimić, Goran ; Folnegović Šmalc, Vera ; Muck-Seler, Dorotea
Izvornik
Progress in neuro-psychopharmacology & biological psychiatry (0278-5846) 44
(2013);
94-99
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Alzheimer’s disease; Cognitive decline; dopamine beta-hydroxylase; DBH gene polymorphisms; plasma DBH activity
Sažetak
The noradrenergic system is involved in the etiology and progression of Alzheimer’s disease (AD) but its role is still unclear. Dopamine beta-hydroxylase (DBH) as a catecholamine-synthesizing enzyme plays a central role in noradrenaline (NA) synthesis and turnover. Plasma DBH (pDBH) activity shows wide inheritable interindividual variability that is under genetic control. The aim of this study was to determine pDBH activity, DBH (C-970T ; rs1611115) and DBH (C1603T ; rs6271) gene polymorphisms in 207 patients with AD and in 90 healthy age-matched controls. Plasma DBH activity was lower, particularly in the early stage of AD, compared to values in middle and late stages of the disease, as well as to control values. Two-way ANOVA revealed significant effect of both diagnosis and DBH (C-970T) or DBH (C1603T) genotypes on pDBH activity, but without significant diagnosis x genotype interaction. No association was found between AD and DBH C-970T (OR = 1.08, 95% CI 1.13-4.37 ; p = 0.779) and C1603T (OR = 0.89 ; 95% CI 0.36-2.20 ; p = 0.814) genotypes controlled for age, gender, and ApoE4 allele. The decrease in pDBH activity, found in early phase of AD suggests that alterations in DBH activity represent a compensatory mechanism for the loss of noradrenergic neurons, and that treatment with selective NA reuptake inhibitors may be indicated in early stages of AD to compensate for loss of noradrenergic activity in the locus coeruleus.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
098-0982522-2455 - Molekularna podloga i liječenje psihijatrijskih i stresom izazvanih poremećaja (Pivac, Nela, MZOS ) ( CroRIS)
098-0982522-2457 - Farmakogenomika i proteomika serotoninskog i kateholaminskog sustava (Muck-Šeler, Dorotea, MZOS ) ( CroRIS)
108-1081870-2418 - BAP, shizoafektivni poremećaj,shizofrenija:Različite bolesti ili kontinuum? (Folnegović-Šmalc, Vera, MZOS ) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb,
Klinika za psihijatriju Vrapče,
Psihijatrijska bolnica "Sveti Ivan" Zagreb
Profili:
Goran Šimić
(autor)
Vera Folnegović-Šmalc
(autor)
Dorotea Muck-Šeler
(autor)
Maja Mustapić
(autor)
Nela Pivac
(autor)
Ninoslav Mimica
(autor)
Paola Presečki
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- BIOSIS Previews (Biological Abstracts)
- EMBASE (Excerpta Medica)
- MEDLINE